HLB Therapeutics Co.,Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 15 million compared to KRW 331.85 million a year ago. Net income was KRW 3,185.73 million compared to net loss of KRW 1,905.15 million a year ago. Basic earnings per share from continuing operations was KRW 44.6763 compared to basic loss per share from continuing operations of KRW 28.7729 a year ago. Diluted earnings per share from continuing operations was KRW 44.57 compared to diluted loss per share from continuing operations of KRW 28.7729 a year ago. Basic earnings per share was KRW 43.7101 compared to basic loss per share of KRW 28.9855 a year ago. Diluted earnings per share was KRW 43.6039.
For the six months, sales was KRW 15 million compared to KRW 354.96 million a year ago. Net income was KRW 2,877.26 million compared to net loss of KRW 3,870.22 million a year ago. Basic earnings per share from continuing operations was KRW 42.5894 compared to basic loss per share from continuing operations of KRW 59.1304 a year ago. Diluted earnings per share from continuing operations was KRW 42.5024 compared to diluted loss per share from continuing operations of KRW 59.1304 a year ago. Basic earnings per share was KRW 39.6908 compared to basic loss per share of KRW 59.9034 a year ago. Diluted earnings per share was KRW 39.6039.